@pubmed.ncbi.nlm.nih.gov.rss-feed.feed.id.1bkd3nt7c-bb2ox2p4gq17anukdwtgc2lcfjxpodg3qewx1czi.utm.content.1bkd3nt7c-bb2ox2p4gq17anukdwtgc2lcfjxpodg3qewx1czi.utm.medium.rss.ff.20260423180744.utm.source.rss-parrot-bot.v.2.19.0.post6.133c1fe@rss-parrot.net
I'm an automated parrot! I relay a website's RSS feed to the Fediverse. Every time a new post appears in the feed, I toot about it. Follow me to get all new posts in your Mastodon timeline! Brought to you by the RSS Parrot.
---
Multiple [TIAB] AND sclerosis [TIAB] AND therapy [TIAB] AND trial: Latest results from PubMed
Feed URL: pubmed.ncbi.nlm.nih.gov/rss/search/1BKD3NT7c-BB2OX2P4gq17ANUKDwTGC2lCFjxpodg3qEwx1cZI/
Posts: 10
Followers: 1
Biological and clinical stability after switching from intravenous to subcutaneous natalizumab in RRMS under standard and extended dosing
Published: August 6, 2026 10:00
CONCLUSION: Switching from IV to SC NTZ while maintaining either standard (4w) or extended (6w) dosing intervals preserves pharmacodynamic stability, as reflected by sustained CD49d RO, stable sNfL levels, and consistent clinical outcomes. These findings…
Efficacy and safety of mesenchymal stem cell transplantation for progressive multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials with clinical implications for patient stratification and treatment optimization
Published: August 6, 2026 10:00
CONCLUSION: MSC transplantation appears safe in PMS patients, with no increased adverse event risk. However, current evidence does not support significant benefit on EDSS scores in unselected patients. Given the very low to moderate certainty, further…
French expert opinion on the long-term management of relapsing multiple sclerosis with cladribine tablets beyond year 4
Published: August 4, 2026 10:00
Cladribine tablets (CladT) is a high-efficacy treatment (HET) for the management of relapsing multiple sclerosis (RMS) that acts as an immune reconstitution therapy (IRT). Administered as two short annual courses, CladT has been shown to provide durable…
Efficacy and safety of cannabinoids in the treatment of spasticity in multiple sclerosis: A systematic review of randomized clinical trials
Published: August 3, 2026 10:00
CONCLUSIONS: Cannabinoids provide modest improvements in patient-reported spasticity in MS, with more consistent effects for THC:CBD extracts. Given the low certainty of evidence and limited objective benefits, cannabinoids should be considered cautiously…
Real-world practices and challenges of radiologically isolated syndrome: results of a cross-sector survey by the DACH MS guidelines group
Published: July 30, 2026 10:00
CONCLUSION: Real-world RIS care in the DACH region is characterized by substantial practice heterogeneity, coexisting with shared clinical approaches, which reflects the absence of formal guidelines and approved therapies. While the 2024 McDonald criteria…
Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis
Published: July 24, 2026 10:00
Clinically silent MRI lesions occur frequently in people with relapsing-remitting multiple sclerosis (RRMS) despite disease modifying therapy (DMT). Guidelines only routinely recommend DMT escalation after multiple silent lesions, and adherence is…
Tailoring disease-modifying therapy approaches across multiple sclerosis sub-populations
Published: July 23, 2026 10:00
While advances in anti-inflammatory disease-modifying therapies (DMTs) have transformed multiple sclerosis (MS) care, treatment recommendations are not necessarily applicable or uniform across all populations. This narrative review synthesizes contemporary…
Targeting progressive multiple sclerosis: Toward mechanism-informed precision medicine
Published: July 21, 2026 10:00
Multiple sclerosis has undergone a therapeutic revolution over the past three decades. Randomized clinical trials and real-world data demonstrate that modern disease-modifying therapies substantially reduce relapse rates and acute inflammatory activity…
Clinical and cost-effectiveness of the iStep-MS physical activity and sedentary behaviour intervention for managing fatigue in people with multiple sclerosis: protocol for a multicentre randomised controlled trial
Published: July 20, 2026 10:00
INTRODUCTION: Regular physical activity and limiting sedentary behaviour are important aspects in managing multiple sclerosis (MS). Fatigue is a common and disabling symptom in MS, contributing to impairments in activities of daily living and poorer…
Educational programs based on healthy habits to improve quality of life and psychosocial profile in women with multiple sclerosis: The ADVICE protocol study
Published: July 16, 2026 10:00
CONCLUSIONS: This study will provide novel insights into how MC influence fatigue, physical activity satisfaction, and strength training responses in women with RRMS and without MS, as well as the comparative effects of supervised versus self-guided…